We are live on ! Find out more
BVF Inc

BVF Inc Portfolio holdings

AUM $3.91B Turnover 15.22%
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
-8.24%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.93%
10 Year Est. Return
+28,184.7%
AUM
$482M
AUM Growth
-$151M
Cap. Flow
-$70.7M
Cap. Flow %
-14.68%
Top 10 Hldgs %
78.28%
Holding
34
New
5
Increased
8
Reduced
7
Closed
2
Avg Time Held
0.8 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
0.8 years

Sector Composition

Rank Sector Weight
1 Healthcare 78.72%
2 Miscellaneous 21.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$800M
$72.5M 15.06%
6,682,896
-4,312,541
-39% -$49.4M
2013 Q2
5 quarters
RCPT
2
DELISTED
Receptos
RCPT
$71.2M 14.78%
1,146,300
+235,700
+26% +$11.3M
2013 Q2
5 quarters
LGND icon
3
Ligand Pharmaceuticals
LGND
$6.03B
$52.1M 10.82%
1,777,347
-1,257,329
-41% -$41.7M
2013 Q2
5 quarters
ARRY icon
4
DELISTED
Array Biopharma
ARRY
$49.5M 10.29%
13,876,513
-839,273
-6% -$3.31M
2013 Q2
5 quarters
CCXI icon
5
DELISTED
ChemoCentryx
CCXI
$38.7M 8.03%
8,596,772
+414,956
+5% +$2.19M
2013 Q2
5 quarters
OMED
6
DELISTED
OncoMed Pharmaceuticals
OMED
$24.4M 5.06%
1,287,847
+462,200
+56% +$9.29M
2013 Q3
4 quarters
CASC
7
DELISTED
Cascadian Therapeutics
CASC
$18.9M 3.93%
1,644,546
+1,500
+0.1% +$22.9K
2013 Q2
5 quarters
FPRX
8
DELISTED
Five Prime Therapeutics
FPRX
$17.1M 3.56%
1,461,900
+208,900
+17% +$2.64M
2013 Q4
3 quarters
GYRE icon
9
Gyre Therapeutics
GYRE
$495M
$16.8M 3.5%
8,451
– –
2013 Q2
5 quarters
LOXO
10
DELISTED
Loxo Oncology
LOXO
$15.7M 3.25%
+1,192,202
New +$15.5M
2014 Q3
0 quarters
CNCE
11
DELISTED
Concert Pharmaceuticals
CNCE
$15.2M 3.16%
+1,206,459
New +$11.7M
2014 Q3
0 quarters
QLTI icon
12
DELISTED
QLT Inc
QLTI
$9.46M 1.96%
2,093,563
-276,700
-12% -$1.56M
2013 Q2
5 quarters
PRQR icon
13
ProQR Therapeutics
PRQR
$172M
$9.44M 1.96%
+549,000
New +$8.8M
2014 Q3
0 quarters
TRVN icon
14
DELISTED
Trevena
TRVN
$7.18M 1.49%
1,790
– –
2014 Q1
2 quarters
ARDX icon
15
Ardelyx
ARDX
$767M
$6.44M 1.34%
+453,541
New +$6.56M
2014 Q3
0 quarters
CYTK icon
16
Cytokinetics
CYTK
$7.42B
$5.38M 1.12%
1,527,000
+210,000
+16% +$882K
2013 Q2
5 quarters
VTAE
17
DELISTED
Vitae Pharmaceuticals
VTAE
$5.08M 1.06%
+666,000
New +$5.18M
2014 Q3
0 quarters
ARQL
18
DELISTED
Arqule
ARQL
$4.82M 1%
4,300,887
+1,176,000
+38% +$1.55M
2013 Q2
5 quarters
TBRA
19
DELISTED
Tobira Therapeutics
TBRA
$2.95M 0.61%
289,677
– –
2013 Q3
4 quarters
BLRX icon
20
BioLineRX
BLRX
$5.87M
$2.31M 0.48%
2,502
– –
2014 Q1
2 quarters
KBIO
21
DELISTED
KaloBios Pharmaceuticals
KBIO
$1.8M 0.37%
145,250
– –
2014 Q2
1 quarter
QUIT icon
22
Achieve Life Sciences
QUIT
$668M
$1.77M 0.37%
301
-91
-23% -$632K
2014 Q2
1 quarter
SPHS
23
DELISTED
Sophiris Bio
SPHS
$1.76M 0.37%
600,000
– –
2013 Q3
4 quarters
RGLS icon
24
DELISTED
Regulus Therapeutics
RGLS
$1.26M 0.26%
1,542
– –
2013 Q2
5 quarters
AKAO
25
DELISTED
Achaogen Inc
AKAO
$1.22M 0.25%
136,600
+11,600
+9% +$119K
2014 Q1
2 quarters

Similar funds

BVF Inc's Q3 2014 Portfolio in Review

As of Q3 2014, BVF Inc held 34 positions worth $482M, down 24% from $632M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

BVF Inc withdrew a net $70.7M in Q3 2014, closing 2 positions and reducing 7 holdings. Its most notable exit was Exelixis, an estimated $3.39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

Against the trend, BVF Inc opened a new position in Loxo Oncology worth $15.7M.

  • BVF Inc's largest Q3 2014 buy was Loxo Oncology: 1,192,202 shares worth $15.7M.
  • BVF Inc added most to Receptos in Q3 2014, an estimated $11.3M increase.
  • BVF Inc's biggest Q3 2014 reduction was Ironwood Pharmaceuticals, cutting an estimated $49.4M.
  • BVF Inc fully exited Exelixis in Q3 2014, selling an estimated $3.39M.
  • BVF Inc's ten largest holdings make up 78% of its $482M portfolio in Q3 2014.
  • BVF Inc opened 5 new positions and closed 2 in Q3 2014.
  • BVF Inc's portfolio value fell 24% quarter-over-quarter to $482M.

Based on BVF Inc's 13F filing for Q3 2014, filed 14 Nov 2014.